Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium (MHSRS)
August 28, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Oral presentation highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant improvement in primary...
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Global Subsea Trencher Market Size To Worth USD 547.35 Million By 2033 | CAGR Of 5.59%
August 28, 2024 07:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The Global Subsea Trencher Market Size is to Grow from USD 317.59 Million in 2023 to USD 547.35 Million by 2033, at a Compound Annual...
Lotus Technology Reports Unaudited Second Quarter and First Half 2024 Financial Results
August 28, 2024 07:00 ET
|
Lotus Technology Inc.
Robust start in 2024, marking the strongest first half-year performance in the brand’s history.Balanced global allocation, with strong US deliveries1 contribution after the brand’s re-entry into the...
ATHA Energy Provides Summer Update on 2024 Exploration Programs
August 28, 2024 07:00 ET
|
ATHA Energy Corp.
2024 GEMINI EXPLORATION PROGRAM Phase III: Diamond Drilling – commenced in late August and is designed to test for expansion areas at Gemini Mineralized Zone (“GMZ”), as well as targeting highly...
Chemomab Therapeutics to Present at September 2024 Investor Conferences
August 28, 2024 07:00 ET
|
Chemomab Therapeutics
Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September
Xali Gold Advances on Two Fronts at El Oro
August 28, 2024 07:00 ET
|
Xali Gold Corp.
VANCOUVER, British Columbia, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Xali Gold Corp. (TSXV:XGC) ("Xali Gold” or “the Company”) is pleased to advise that it now has two active projects in the El Oro Mining...
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
August 28, 2024 07:00 ET
|
Revive Therapeutics Ltd.
TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Bolt Biotherapeutics to Participate in Upcoming September Conferences
August 28, 2024 07:00 ET
|
Bolt Biotherapeutics, Inc.
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer,...
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
August 28, 2024 07:00 ET
|
Krystal Biotech, Inc.
Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...